The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes

Noto, Hiroshi; Chitkara, Pranav; Raskin, Philip

doi:10.1016/j.jdiacomp.2006.07.004

Cited by 39 publications

(37 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings also differed from the results of Blankenberg et al (2003), who found that the Lp-PLA 2 levels were diminished in cases of CAD patients with hypertension when compared with nonhypertensive patients. Finally, in the present study, triglyceride was also associated with Lp-PLA 2 activity, a finding that has been observed previously (Noto et al 2006).…”

Section: Discussionsupporting

confidence: 92%

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated with Progression of Nonculprit Lesions after Percutaneous Coronary Intervention

Hui

Gong

Cai

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Lipoprotein-associated phospholipase A2 (Lp-PLA 2 ) is an enzyme that hydrolyzes oxidized phospholipids to generate bioactive proatherogenic products. Nonculprit lesions have been assumed to contribute to the pathogenesis of recurrent acute coronary syndrome (ACS). The role of LP-PLA 2 in the progression of nonculprit coronary lesions after successful percutaneous coronary intervention (PCI) remains unclear. Our study included 123 patients with ACS who underwent initial PCI and a long-term follow-up (mean interval, one year) with coronary angiography. Among them, 19 patients were diagnosed as the progression of nonculprit lesions, based on the presence of at least one of the following factors: (1) ≥ 10% reduction in the diameter of a preexisting ≥ 50% stenosis; (2) ≥ 30% reduction in the diameter of a < 50% stenosis; and (3) early-onset stenosis with ≥ 30% reduction in the diameter of a segment that was normal on the primary angiogram. Blood sampling was drawn from all patients at 12-14 hours after PCI. The ACS patients with progression had higher total cholesterol (4.47 ± 1.02 mmol/L vs. 3.59 ± 0.57 mmol/L, P < 0.05), higher levels of Lp-PLA 2 activity (14.39 ± 6.13 nmol/min/ml vs. 8.86 ± 3.14 nmol/min/ml, P < 0.001) and a higher proportion of multi-vessel disease than those without progression. Multivariate logistic regression analysis showed that Lp-PLA 2 activity (β = 0.024, P = 0.005) was an independent predictor for rapid progression of nonculprit coronary lesions. In conclusion, elevated Lp-PLA2 activity is associated with rapid progression of nonculprit coronary lesions in ACS patients who underwent PCI.

show abstract

Section: Discussionsupporting

confidence: 92%

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated with Progression of Nonculprit Lesions after Percutaneous Coronary Intervention

Hui

Gong

Cai

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Not surprisingly, Lp-PLA2 was strongly associated with LDL-cholesterol because LDL is the major carrier of Lp-PLA2. 22 Lp-PLA2 mass levels were strongly correlated positively with triglycerides, age, and total cholesterol and moderately negatively correlated with HDL-cholesterol, as reported in previous studies. 23,24 The prevalence of chronic inflammation is high in dialysis patients and C-reactive protein (CRP) is a widely used inflammatory marker.…”

Section: Discussionsupporting

confidence: 87%

Effects of Lipoprotein-Associated Phospholipase A2 on Arginase/Nitric Oxide Pathway in Hemodialysis Patients

et al. 2012

View full text Add to dashboard Cite

Lipoprotein-associated phospholipase A2 (Lp-PLA2) and arginase are recently described inflammatory biomarkers associated with cardiovascular disease. In this study, we aimed to investigate the possible effects of serum Lp-PLA2 mass levels on arginase/nitric oxide (NO) pathway as a cardiovascular risk marker in hemodialysis (HD) patients. Fortythree HD patients and 15 healthy subjects were included in this study. Lipid profile, high sensitivity C-reactive protein (hs-CRP), albumin, creatinine, body mass index (BMI), Lp-PLA2 and total nitrite levels, and arginase activity were determined in serum samples from patients and control subjects. Lp-PLA2 levels were found to be positively correlated with arginase, triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and age and negatively correlated with high-density lipoprotein-cholesterol and total nitrite levels, while there was no correlation with BMI and hs-CRP, albumin, and creatinine levels in HD patients. We conclude that elevated Lp-PLA2 mass levels may contribute to impaired arginase/ NO pathway in HD patients and that increased the arginase activity and Lp-PLA2 mass levels with decreased total nitrite levels seem to be useful biochemical markers in terms of reflecting endothelial dysfunction and associated cardiovascular risks in HD patients.

show abstract

“…and oxidized fatty acids that are stimulating inflam-matory cytokines might well function as a comprehensive marker of MetS in diabetic subjects on insulin, it may not represent insulin resistance in MetS (20). But in our study there was not any relationship between number of MetS components and Lp-PLA2 level.…”

Section: Discussioncontrasting

confidence: 66%

Does Lipoprotein-Associated Phospholipase A2 Level Correlate with Insulin Resistance States in Metabolic Syndrome, an Early Atherosclerotic Phase?

Sagun¹

2011

Acta Endo (Buc)

View full text Add to dashboard Cite

Background. Lipoprotein-associated phospholipase A2 is a novel inflammation marker that generates pro-inflammatory molecules from oxidized LDL.Aim. We aimed to investigate its role in individuals with insulin resistance and metabolic syndrome which is representative of early stages of atherosclerosis.Methods. We evaluated 114 subjects with metabolic syndrome in a cross-sectional pattern. Waist circumference was measured. Fasting plasma glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), LDL-cholesterol (LDL-C), fasting insulin were measured by standard assays. Oral glucose tolerance test was applied to patients with fasting blood glucose < 126 mg/dL. Patients were classified to tertiles according to their insulin resistance states. Lp-PLA2 mass levels were measured.Results. There was a correlation between hypertension and HOMA tertiles; HDL-C, hypertriglyceridemia, hyperglycemia were not correlated with HOMA tertiles (p = 0.024, p=0.66, p=0.66, p = 0.18, respectively). We cannot find any association between HOMA tertiles and Lp-PLA2 levels. Triglyceride was negatively correlated with Lp-PLA2. Conclusion.Lp-PLA2 is not correlated with insulin resistance in subjects with metabolic syndrome.

show abstract

The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes

Cited by 39 publications

References 39 publications

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated with Progression of Nonculprit Lesions after Percutaneous Coronary Intervention

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated with Progression of Nonculprit Lesions after Percutaneous Coronary Intervention

Effects of Lipoprotein-Associated Phospholipase A2 on Arginase/Nitric Oxide Pathway in Hemodialysis Patients

Does Lipoprotein-Associated Phospholipase A2 Level Correlate with Insulin Resistance States in Metabolic Syndrome, an Early Atherosclerotic Phase?

Contact Info

Product

Resources

About